Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells.
Wangpaichitr M, Sullivan EJ, Theodoropoulos G, Wu C, You M, Feun LG, Lampidis TJ, Kuo MT, Savaraj N.
Mol Cancer Ther. 2012 Mar;11(3):604-15. Epub 2012 Jan 16.
Related citations
Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.
Wilson PM, LaBonte MJ, Lenz HJ, Mack PC, Ladner RD.
Mol Cancer Ther. 2012 Mar;11(3):616-28. Epub 2011 Dec 15.
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K.
Mol Cancer Ther. 2012 Jan;11(1):204-13. Epub 2011 Nov 10.
Rapamycin induces bad phosphorylation in association with its resistance to human lung cancer cells.
Liu Y, Sun SY, Owonikoko TK, Sica GL, Curran WJ, Khuri FR, Deng X.
Mol Cancer Ther. 2012 Jan;11(1):45-56. Epub 2011 Nov 4.
Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.
Tsai MS, Weng SH, Chen HJ, Chiu YF, Huang YC, Tseng SC, Kuo YH, Lin YW.
Mol Cancer Ther. 2012 Mar;11(3):561-71. Epub 2011 Nov 3.
Methylation profiling of lung cancer: a decade of progress.
Toyooka S, Gazdar AF.
Mol Cancer Ther. 2011 Nov;10(11):2020. No abstract available.
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.
Zhang C, Elkahloun AG, Liao H, Delaney S, Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ, Dennis PA.
Mol Cancer Ther. 2011 Jul;10(7):1137-48. Epub 2011 May 6.
Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.
Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, Shimizu K, Tanimoto M, Kiura K.
Mol Cancer Ther. 2011 Sep;10(9):1720-7. Epub 2011 Jun 28.
E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.
Ogino H, Hanibuchi M, Kakiuchi S, Trung VT, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.
Mol Cancer Ther. 2011 Jul;10(7):1218-28. Epub 2011 May 6.
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D.
Mol Cancer Ther. 2011 May;10(5):806-16. Epub 2011 Mar 18.
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD.
Mol Cancer Ther. 2011 Feb;10(2):336-46.
Cancer-targeted BikDD gene therapy elicits protective antitumor immunity against lung cancer.
Sher YP, Liu SJ, Chang CM, Lien SP, Chen CH, Han Z, Li LY, Chen JS, Wu CW, Hung MC.
Mol Cancer Ther. 2011 Apr;10(4):637-47. Epub 2011 Jan 31.
Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells.
Gupta S, Koru-Sengul T, Arnold SM, Devi GR, Mohiuddin M, Ahmed MM.
Mol Cancer Ther. 2011 Feb;10(2):292-302. Epub 2011 Jan 7.
JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Song L, Rawal B, Nemeth JA, Haura EB.
Mol Cancer Ther. 2011 Mar;10(3):481-94. Epub 2011 Jan 7.
Lysophosphatidylcholine pretreatment reduces VLA-4 and P-Selectin-mediated b16.f10 melanoma cell adhesion in vitro and inhibits metastasis-like lung invasion in vivo.
Jantscheff P, Schlesinger M, Fritzsche J, Taylor LA, Graeser R, Kirfel G, Fürst DO, Massing U, Bendas G.
Mol Cancer Ther. 2011 Jan;10(1):186-97.
Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition.
Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, Keshamouni VG.
Mol Cancer Ther. 2010 Dec;9(12):3221-32.
Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice.
Wang Y, James M, Wen W, Lu Y, Szabo E, Lubet RA, You M.
Mol Cancer Ther. 2010 Nov;9(11):3074-82. Epub 2010 Nov 2.
Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer.
Ichite N, Chougule M, Patel AR, Jackson T, Safe S, Singh M.
Mol Cancer Ther. 2010 Nov;9(11):3003-14. Epub 2010 Oct 26.
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
Mol Cancer Ther. 2010 Oct;9(10):2785-92. Epub 2010 Aug 17.
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Nagji AS, Cho SH, Liu Y, Lee JK, Jones DR.
Mol Cancer Ther. 2010 Oct;9(10):2834-43. Epub 2010 Aug 16.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on